ENDRA Life Sciences Inc.
NDRA
$4.84
-$0.44-8.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -74.29% | 412.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -65.80% | 184.74% | |||
| Operating Income | 65.80% | -184.74% | |||
| Income Before Tax | 75.02% | -76.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 75.02% | -76.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 75.02% | -76.25% | |||
| EBIT | 65.80% | -184.74% | |||
| EBITDA | 66.04% | -186.19% | |||
| EPS Basic | 75.83% | 19.39% | |||
| Normalized Basic EPS | 75.83% | 19.39% | |||
| EPS Diluted | 75.83% | 19.39% | |||
| Normalized Diluted EPS | 75.83% | 19.39% | |||
| Average Basic Shares Outstanding | 3.34% | 118.64% | |||
| Average Diluted Shares Outstanding | 3.34% | 118.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||